BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ewopharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Ewopharma's drugs run\, from Clin
 icalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05700448-2747@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Cejemly (Sugemalimab): Phase 3 readout est. (NCT05700448)
DESCRIPTION:Cejemly (Sugemalimab)\, phase 3.\nStudy: Study of Sugemalimab (
 or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell 
 Lymphoma\nEstimated primary completion: December 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sugemalimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05700448
URL:https://assetmemo.bio/drug/sugemalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
